Despite many successes in 2023, the biotechnology industry saw a year-on-year decline in market capitalisation for the first time since 2012, according to GEN’s A-list. The largest biotech companies closed the year with a total market cap of $1.711 trillion, down 2.2% from the previous year. The decline reflects falling vaccine sales, increasing financial insecurity, and upcoming patent expiration for several major drugs.
The True Cost of Focusing on Cost Instead of Cost-Effectiveness
When payors consider only the cost of the medication and not the cost and risk to the patient, doctor, and healthcare system, the irony is
